期刊文献+

SLE患者血中调节性T细胞及TGF-β_1的表达 被引量:2

Peripheral Blood Expression of T Regulatory Cells,TGF-β_1 and Anti-ds DNA Antibody in Patients with SLE
下载PDF
导出
摘要 目的:检测系统性红斑狼疮(SLE)轻型与重型患者中调节性T细胞、TGF-β1和抗ds-DNA抗体的表达水平,并与正常健康人对比,分析它们之间的差异。方法:应用放射免疫分析和ELISA检测血清抗ds-DNA和TGF-β1的表达水平,采用流式细胞仪检测调节性T细胞的表达水平。结果:狼疮重型组中调节性T细胞显著低于狼疮轻型组和健康对照组(P<0.05);重型组抗ds-DNA抗体显著高于轻型组和健康对照组(P<0.05);重型与轻型的TGF-β1的表达水平差异无统计学意义,但重型组和轻型组的表达水平都比健康对照组明显降低。结论:调节性T细胞的表达数量可作为狼疮活动的指标,而血清TGF-β1的表达水平与其活动性无关。 Objective To study the changes of peripheral blood expression of T regulatory cells, TGF-β1 and anti-dsDNA antibody in patients with SLE. Methods Peripheral blood T regulatory cell proportion (with flow-cytometry) and serum anti-dsDNA antibody (with RIA), TGF-β1 (with ELISA) expressions were examined in ① 94 SLE patients in active stage ② 60 SLE patients in stable stage and ③ 60 controls. Results The T regulatory proportion in SLE patients in active stage was significantly lower than that in SLE patients in stable stage and controls (P〈0.05), while the anti-dsDNA antibody expression was significantly higher (P also 〈0.05). The TGF-β1 expressions in the active and stable SLE patients were not significantly different, but they were significantly lower than that in controls. Conclusion Peripheral blood T regulatory cell proportion decreased during active stage in SLE patients, but TGF-β1 expression was not related to the activity of the disease.
出处 《放射免疫学杂志》 CAS 2010年第6期605-608,共4页 Journal of Radioimmanology
基金 南京市医学科技发展项目(YKK07033)
关键词 重症狼疮 调节性T细胞 转化生长因子β1( TGF-β1) 抗DS-DNA抗体 severe systemic lupus erythematosus regulatory T cells transforming growth factor-β1 anti-dsDNA
  • 相关文献

参考文献2

二级参考文献1

共引文献30

同被引文献28

  • 1孙保东,谭艳红,冯小欣,梁晓萍,蔡文虹,肖学吕.血清转化生长因子β1的表达在系统性红斑狼疮发病中的意义[J].临床和实验医学杂志,2006,5(7):906-907. 被引量:4
  • 2陈伟,李向培,翟志敏,陶金辉,李庆,张宏,钱龙.系统性红斑狼疮患者外周血调节性T细胞与TGF-β水平变化及其意义[J].山东医药,2006,46(32):11-13. 被引量:4
  • 3Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [ J]. Arthritis Rheum, 1997,40 (9) :1725.
  • 4Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000 [ J]. J Rheumatol, 2002, 29 ( 2 ) : 288-291.
  • 5Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase B : a tuner and amplifier of immune functions [ J ]. Trends Immunol,2001, 22(10) :571 -579.
  • 6Mawrin C, Brunn A, Rocken C, et al. Peripheral neuropathy in systemic lupus erythematosus:pathomorphological features and distribution pattern of matrix metalloproteinases [ J ]. Acta Neuropathol, 2003,105 (4) :365-372.
  • 7Chang YH, Lin IL, Tsay G J, et al. Elevated circulatory MMP-2 and MMP9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus [ J ]. Clin Biochem ,2008,41 (12) : 955-959.
  • 8Robak E, Wierzbowska A, Chmiela M, et al. Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus [ J]. Mediators Inflamm,2006, ( 1 ) :17898.
  • 9Kehrl JH, Thevenin C, Rieckmann P, et al. Transforming growth factor-beta suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA[ J]. J Immunol, 1991,146 ( 11 ) :4016 -4023.
  • 10Vila J,Isaacs JD,Anderson AE.Regulatory T cells and autoimmunity[J].Curr Opin Hematol,2009,16(4):274-279.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部